The Efficacy of Infliximab Monotherapy versus Infliximab-Azathioprine Sequential Treatment in Crohn’s Disease: Experience from a Tertiary Medical Center in China

Table 1

Baseline characteristics of our study.

Variables	IFX monotherapy group ()	IFX-AZA sequential therapy group ()	All ()	value
Male sex, (%)	16 (72.7)	38 (66.7)	54 (68.4)	0.604
Duration of symptoms (week)				0.733
Age of onset (yr)				0.217
Location of lesions, (%)				0.829
Ileum	6 (27.3)	20 (35.1)	26 (32.9)
Colon	3 (13.6)	6 (10.5)	9 (11.4)
Ileocolon	12 (54.5)	30 (52.6)	42 (53.2)
Upper GI tract	1 (4.5)	1 (1.8)	2 (2.5)
Behavior of disease, (%)				0.252
Nonstenosis, nonfistula	14 (63.6)	46 (80.7)	60 (75.9)
Stenosis	4 (18.2)	7 (12.3)	11 (13.9)
Fistula	4 (18.2)	4 (7.0)	8 (10.1)
Perianal disease, (%)	9 (40.9)	20 (35.1)	29 (36.7)	0.630
CDAI				0.457
CDEIS				0.964
Deep remission at week 30	13 (59.1)	31 (54.4)	44 (55.7)	0.706
Complete endoscopic remission at week 30	13 (59.1)	31 (54.4)	44 (55.7)	0.706
Endoscopic remission at week 30	19 (86.4)	42 (73.7)	61 (77.2)	0.365
Endoscopic improvement at week 30	21 (95.5)	54 (94.7)	75 (94.9)	0.999